Management of the adnexal mass

Obstetrics and Gynecology

Volumn 117, Issue 6, 2011, Pages 1413-1428

  Liu, James H ^a   Zanotti, Kristine M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN;

ADNEXA DISEASE; AGE; ALGORITHM; ARTICLE; CANCER RISK; CYSTECTOMY; DIAGNOSTIC TEST; EPIDEMIOLOGY; EVIDENCE BASED PRACTICE; FAMILY HISTORY; HUMAN; LAPAROSCOPY; LAPAROTOMY; MORBIDITY; MORTALITY; OVARIECTOMY; OVARY CANCER; PATIENT REFERRAL; PELVIC EXAMINATION; PHYSICIAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; RISK FACTOR; SCORING SYSTEM; SWEAT GLAND TUMOR; SYMPTOM;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 79958090998     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821c62b6     Document Type: Article

References (97)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Evidence report/technology assessment No. 130. AHRQ Publication No. 06-E004. Rockville (MD): Agency for Healthcare Research and Quality; 2006.
3. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al. SGO White paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol 2010;119:7-17.
4. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 2004;22:1315-27.
5. Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer; defining the target for early detection. PLoS Med 2009;6:e1000114.
6. DiSaia PJ, Creasman WT. Clinical gynecologic oncology. 7th ed. St. Louis (MO): Mosby; 2007.
7. Hoskins WJ. Principles and practice of gynecologic oncology. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005:1419.
8. Jain KA. Sonographic spectrum of hemorrhagic ovarian cysts. J Ultrasound Med 2002;21:879-86. (Pubitemid 34827468)
9. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161-92.
10. Kurman RJ. Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-60. (Pubitemid 351450677)
11. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
12. Surveillance epidemiology and end results. SEER incidence statistics: ovarian carcinoma. Available at: http://seer.cancer.gov/ statistics. Accessed April 25, 2011.
13. Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 2003;97: 519-23.
14. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer. 1995;72:805-12.
15. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL Eisen A, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006;24:863-71. (Pubitemid 46638837)
16. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65.
17. Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6: 105-10. (Pubitemid 27033972)
18. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988; 128:456-66.
19. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:957-66.
20. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068-75.
21. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221-7. (Pubitemid 46106236)
22. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005;112:857-65. (Pubitemid 40896949)
23. Lurie G, Thompson PJ, McDuffie KE, Carney ME, Goodman MT. Prediagnostic symptoms of ovarian carcinoma: a casecontrol study. Gynecol Oncol 2009;114:231-6.
24. Lowe KA, Andersen MR, Urban N, Paley P, Dresher, CW, Goff BA. The temporal stability of the symptom index among women at high-risk for ovarian cancer. Gynecol Oncol 2009; 114:225-30.
25. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010;102:222-9.
26. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001;84:714-21. (Pubitemid 32239010)
27. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007;166:894-901. (Pubitemid 47511685)
28. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006;98: 1397-405. (Pubitemid 44530716)
29. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 2006;85:819.
30. Jensen A, Sharif H, Frederiksen K, Kjaer S. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort. BMJ 2009;338:249.
31. Black ER, Bordley DR, Tape TG, Panzer RJ, editors. Diagnostic strategies for common medical problems. 2nd ed. Philadelphia (PA): American College of Physicians; 1999.
32. Richardson WS. Five uneasy pieces about pre-test probability. J Gen Intern Med. 2002;17:891-2. (Pubitemid 35370555)
33. Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust 1995;162:408-10.
34. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;15:1685-92.
35. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113: 775-82.
36. Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for the evaluation of the female pelvic organs. Int J Gynecol Obstet 2005;88:84-8. (Pubitemid 40023108)
37. Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci 1996;165:268-70. (Pubitemid 26413406)
38. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72:659-64.
39. Yamashita Y, Torashima M, Hatanaka Y, Harada M, Higashida Y, Takahashi M, et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology 1995;194:557-65.
40. Timmerman D, Schwä rzler P, Collins WP, Claerhout F, Coenen M, Amant F, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999;13:11-6.
41. Granberg S, Norström A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990;37:224-9. (Pubitemid 20182285)
42. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97: 922-9. (Pubitemid 20340625)
43. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70.
44. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11. (Pubitemid 23339256)
45. Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA, et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol 1997;10:192-7. (Pubitemid 27472453)
46. Alcázar JL, Jurado M. Using a logistic model to predict malignancy of adnexal masses based on menopausal status, ultrasound morphology, and color Doppler findings. Gynecol Oncol 1998;69:146-50. (Pubitemid 28247001)
47. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009;113(2 Pt 1):384-94.
48. Kurjak A, Kupesić S. Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. Croat Med J 1999;40:413-20. (Pubitemid 29401662)
49. Kurjak A, Kupesic S, Sparac V, Kosuta D. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol 2000;16:365-71. (Pubitemid 32154675)
50. Geomini PM, Coppus SF, Kluivers KB, Bremer GL, Kruitwagen RF, Mol BW. Is three-dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecol Oncol. 2007;106:153-9. (Pubitemid 46898583)
51. Alcázar JL, Galán MJ, García-Manero M, Guerriero S. Threedimensional sonographic morphologic assessment in complex adnexal masses: preliminary experience. J Ultrasound Med 2003;22:249-54. (Pubitemid 36278741)
52. Alcázar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol 2005;192:807-12. (Pubitemid 40311273)
53. Valentin L, Ameye L, Jurkovic D, Metzger U, Lécuru F, Van Huffel S, Timmerman D. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 2006;27:438-44. (Pubitemid 43735485)
54. Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7. (Pubitemid 13014028)
55. Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.
56. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21(10 Suppl):206s-10s.
57. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23: 7919-26.
58. Lu KH, Skates SJ, Bevers TB, Newland W, Moore RG, Leeds L, et al. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol 2010;28(Suppl):5003.
59. U.S. Food and Drug Administration. FDA news release: FDA clears a test for ovarian cancer. Available at: http://www.fda. gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm 182057.htm. Retrieved September 15, 2010.
60. Ueland F, DeSimone C, Seamon L, Ware R, Goodrich S, Podzielinski I, et al. The OVA1 test improves the preoperative assessment of ovarian tumors. Gynecol Oncol 2010;116:S23.
61. Bailey CL, Ueland FR, Land GL, DePriest PD, Gallion HH, Kryscio RJ, et al. The malignant potential of small cystic ovarian tumours in women over 50 years of age. Gynecol Oncol 1998;69:3-7. (Pubitemid 28201664)
62. Crayford TJ, Campbell S, Bourne TH, Rawson HJ, Collins WP. Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 2000;355:1060-3. (Pubitemid 30162809)
63. Castillo G, Alcázar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004;92: 965-9. (Pubitemid 38251403)
64. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102:594-9. (Pubitemid 37311227)
65. Greenlee RT, Kessel B, Williams CR, et al. Prevalence, incidence, and natural history of simple ovarian cysts among women 55 years old in a large cancer screening trial. Am J Obstet Gynecol 2010;202:373.e1-9.
66. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 1995; 49(Suppl):S9-15.
67. Powell DE, Puls L, van Nagell J Jr. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur? Hum Pathol 1992;23:846-7.
68. Poels LE, Powell De, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.
69. Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and in the United States. Br J Obstet Gynaecol 1992; 99:329-32.
70. Glantz SA. Primer of biostatistics. 6th ed. New York (NY): McGraw-Hill Medical; 2005.
71. Borgfeldt C, Andolf E. Transvaginal sonographic ovarian findings in a random sample of women 25-40 years old. Ultrasound Obstet Gynecol 1999;13:345-50. (Pubitemid 29312644)
72. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. The Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006134. DOI: 10.1002/14651858.CD006134.pub3.
73. Chiaffarino F, Parazzini F, La Vecchia C, Ricci E, Crosignani PG. Oral contraceptive use and benign gynecologic conditions. A review. Contraception 1998;57:11-8. (Pubitemid 28160429)
74. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007;109:1887-96.
75. Templeman CL, Fallat ME, Lam AM, Perlman SE, Hertweck SP, O'Connor DM. Managing mature cystic teratomas of the ovary. Obstet Gynecol Surv. 2000;55:738-45.
76. Kondo W, Bourdel N, Cotte B, Tran X, Botchorishvili R, Jardon K, et al. Does prevention of intraperitoneal spillage when removing a dermoid cyst prevent granulomatous peritonitis? BJOG 2010;117:1027-30.
77. Commerci J, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic evaulation of 517 cases and review of the literature. Obstet Gynecol 1994;84:22-8. (Pubitemid 24202950)
78. Singh P, Yordan E, Wilbanks G, Miller AW, Wee A, et al. Malignancy associated with benign cystic teratomas (dermoid cysts) of the ovary. Singapore J Med 1988;29:30-4.
79. Erzen M, Rakar S, Klancnik B, Syrjänen K, Syrjänen K, Klancar B. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001;83:100-8. (Pubitemid 32959885)
80. Medeiros LR, Fachel JM, Garry R, Stein AT, Furness S. Laparoscopy versus laparotomy for benign ovarian tumours. The Cochrane Database of Systematic Reviews 2005, Issue 20. Art. No.: CD004751. DOI: 10.1002/14651858.CD004751.pub3.
81. Teplin V, Vittinghoff E, Lin F, Learman LA, Richter HE, Kuppermann M. Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. Obstet Gynecol 2007;109(2 Pt 1):347-54. (Pubitemid 46197427)
82. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-8. (Pubitemid 44464065)
83. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180-9. (Pubitemid 46594151)
84. Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994;55(3 Pt 2): S62-72.
85. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007;10:25:2928-37.
86. Medeiros LR, Rosa DD, Edelweiss MI, Stein AT, Bozzetti MC, Zelmanowicz A, et al. Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer 2005;15:192-202. (Pubitemid 40396952)
87. Geomini PM, Zuurendonk LD, Bremer GL, de Graaff J, Kruitwagen RF, Mol BW. The impact of size of the adnexal mass on the accuracy of frozen section diagnosis. Gynecol Oncol 2005;99:362-6. (Pubitemid 41502845)
88. Brun JL, Cortez A, Rouzier R, Callard P, Bazot M, Uzan S, et al. Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. Am J Obstet Gynecol. 2008;199:244.e1-7.
89. Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M. Outcomes in surgery for ovarian cancer. Gynecol Oncol 2002;87:260-7. (Pubitemid 36034645)
90. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006;106:589-98. (Pubitemid 43157622)
91. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2002;84:36-42. (Pubitemid 34056463)
92. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. ACOG Committee Opinion No. 280 American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;100:1413-6.
93. Society of Gynecologic Oncologists. Guidelines for referral to a gynecologic oncologist: rationale and benefits. Gynecol Oncol 2000;78:S1-13.
94. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841-8. (Pubitemid 47508749)
95. Cronje HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the Emil Novak Ovarian Tumor Registry. Am J Obstet Gynecol 1999;180:323-7. (Pubitemid 29093860)
96. Schmeier KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 2008;10:519-23.
97. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.